The Application of Dipeptidyl Peptidase 4 Inhibitor to the Treatment for  Hepatitis C Virus Infection

doi:10.15344/2394-1499/2014/101

Graphy

Profile

New User

New to Graphy Publications? Create an account to get started today.

Create Account For:

Registered Users

Have an account? Sign in now.

Article Menu

Journal Menu

In Collaboration With

How to Cite | Author Information | Publication History

International Journal of Diabetes & Clinical Diagnosis Volume 1 (2014), Article ID 1:IJDCD-101, 1 pages
http://dx.doi.org/10.15344/2394-1499/2014/101

Expert Opinion

The Application of Dipeptidyl Peptidase 4 Inhibitor to the Treatment for Hepatitis C Virus Infection

Hidekatsu Yanai^*, Hisayuki Katsuyama, Hidetaka Hamasaki, Hiroki Adachi, Sumie Moriyama and Akahito Sako

Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan

Corresponding Author Details: Dr. Hidekatsu Yanai, Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Chiba, 272-8516, Japan; E-mail: dyanai@hospk.ncgm.go.jp

Received: 11 June 2014; Accepted: 23 June 2014; Published: 25 June 2014

Citation: Yanai H, Katsuyama H, Hamasaki H, Adachi H, Moriyama S, et al. (2014) The Application of Dipeptidyl Peptidase 4 Inhibitor to the Treatment for Hepatitis C Virus Infection. Int J Diabetes Clin Diagn 1: 101. doi: http://dx.doi.org/10.15344/2394-1499/2014/101

Copyright: © 2014 Yanai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

Riva A, Laird M, Casrouge A, Ambrozaitis A, Williams R, et al. (2014) Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology. View
Söderholm J, Waldenström J, Askarieh G, Pilli M, Bochud PY, et al. (2013) Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. PLoS One 8: e56991. View
Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ (2008) Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 47: 2127- 2133. View
Sell H, Blüher M, Klöting N, Schlich R, Willems M, et al. (2013) Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depotspecific release from adipose tissue in vivo and in vitro. Diabetes Care 36: 4083- 4090. View
Pala L, Rotella CM (2013) The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence. J Diabetes Res 2013: 590456. View
Romacho T, Elsen M, Röhrborn D, Eckel J (2014) Adipose tissue and its role in organ crosstalk. Acta Physiol (Oxf) 210: 733-753. View
El-Zayadi AR, Anis M (2012) Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol 18: 212-224. View
Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, et al. (2008) Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 48: 28-34. View

Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version